Catalyst Wire Dossier Catalyst Wire Dossier

Zandelisib

zandelisib · MEI Pharma, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Zandelisib, covering 2023-12-13 to 2024-02-01. Get the full timeline:

Most recent: Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]

See pricing